Our Sponsors
We would like to thank each of our sponsors for their generous support - as without them this event would not be possible.
For more information on the sponsorship opportunities available, contact Tara Lovegrove at tara.lovegrove@pharmatimes.com

The Association of the British Pharmaceutical Industry (ABPI)
The ABPI exists to make the UK the best place in the world to research, develop and use new medicines and vaccines. We represent companies of all sizes who invest in discovering the medicines of the future.
Our members supply cutting edge treatments that improve and save the lives of millions of people. We work in partnership with Government and the NHS so patients can get new treatments faster and the NHS can plan how much it spends on medicines.
Every day, we partner with organisations in the life sciences community and beyond to transform lives across the UK.
The National Institute for Health and Care Research (NIHR)
The NIHR is funded by the UK government to improve the health and wealth of the nation through research and represents the most integrated health research system in the world. We partner with all funders of research, including the life sciences industry, to:
* support healthcare innovation and technology that will benefit patients now and in the future
* drive faster translation of basic science discoveries into tangible benefits for patients and the economy
* help develop the people who conduct and contribute to applied health research.
About NIHR: www.nihr.ac.uk/industry

Bionical Emas is a global Contract Research Organisation combining Clinical Development, Early Access Program (EAP) and Clinical Trial Supply (CTS) services to pioneer the way life-changing medicines are developed and accessed for patients around the world.
Our range of services enables us to maximise access, collect data and generate evidence at every point along the drug development pathway. This means we can simultaneously address the immediate and future needs of patients.
Our unique business model, with its range of complimentary services and capabilities, provides an entry point to become the preferred partner to many of the world’s leading pharma and biotech companies.

ICON is a world-leading healthcare intelligence and clinical research organisation. From molecule to medicine, we advance clinical research providing outsourced development and commercialisation services to pharmaceutical, biotechnology, medical device and government and public health organisations. We develop new innovations, drive emerging therapies forward and improve patient lives. With headquarters in Dublin, Ireland, ICON employed approximately 41,150 employees in 113 locations in 53 countries as of September 30, 2022. For further information about ICON, visit: www.iconplc.com.

IQVIA (NYSE:IQV) is a leading global provider of advanced analytics, technology solutions and clinical research services to the life sciences industry. IQVIA creates intelligent connections to deliver powerful insights with speed and agility — enabling customers to accelerate the clinical development and commercialization of innovative medical treatments that improve healthcare outcomes for patients. With approximately 82,000 employees, IQVIA conducts operations in more than 100 countries.
Learn more at iqvia.com.

Medable is on a mission to get effective therapies to patients faster by transforming clinical drug development with disruptive technologies. The company’s digital platform streamlines design, recruitment, retention and data quality for decentralized trials, replacing siloed systems with integrated digital tools, data and interfaces to accelerate trial execution. Medable connects patients, sites and clinical trial teams to improve patient access, experience, and outcomes. Medable is a privately held, venture-backed company headquartered in Palo Alto, California.

As a leading global clinical research organization (CRO), Parexel supports the development of innovative new medicines to improve the health of patients. We provide services to help life sciences and biopharmaceutical clients everywhere transform scientific discoveries into new treatments. From decentralized clinical trials to regulatory consulting services and leveraging real-world insights, our therapeutic, technical, and functional ability is underpinned by a patient-first culture embedded in our DNA. Our employees have a deep conviction in what we do, and together with our customers, we are shaping the next generation of therapies, one patient at a time. What we do, we do With Heart™.